These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 32206157)
1. Cell-Free Circulating Tumour DNA Blood Testing to Detect Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157 [TBL] [Abstract][Full Text] [Related]
2. Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2023; 23(9):1-293. PubMed ID: 39364436 [TBL] [Abstract][Full Text] [Related]
3. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857 [TBL] [Abstract][Full Text] [Related]
5. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770 [TBL] [Abstract][Full Text] [Related]
6. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868 [TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402 [TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244 [TBL] [Abstract][Full Text] [Related]
9. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456 [TBL] [Abstract][Full Text] [Related]
10. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616 [TBL] [Abstract][Full Text] [Related]
11. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(14):1-148. PubMed ID: 33240455 [TBL] [Abstract][Full Text] [Related]
13. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972 [TBL] [Abstract][Full Text] [Related]
14. Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2023; 23(8):1-151. PubMed ID: 38130940 [TBL] [Abstract][Full Text] [Related]
15. Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment. Ontario Health Ont Health Technol Assess Ser; 2024; 24(2):1-162. PubMed ID: 38344326 [TBL] [Abstract][Full Text] [Related]
16. Internet-Delivered Cognitive Behavioural Therapy for Post-traumatic Stress Disorder or Acute Stress Disorder: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(9):1-120. PubMed ID: 34527087 [TBL] [Abstract][Full Text] [Related]
17. Level 2 Polysomnography for the Diagnosis of Sleep Disorders: A Health Technology Assessment. Ontario Health Ont Health Technol Assess Ser; 2024; 24(7):1-157. PubMed ID: 39372311 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737 [TBL] [Abstract][Full Text] [Related]
19. Fractional Exhaled Nitric Oxide Testing for the Diagnosis and Management of Asthma: a Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2024; 24(5):1-225. PubMed ID: 39329005 [TBL] [Abstract][Full Text] [Related]
20. Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(12):1-134. PubMed ID: 33240453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]